Metraipolis › archive › dc_d73b8d0d3702

Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy — Europe PMC PMID:41907622

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41907622
DOI
10.3389/fonc.2026.1763278
License (as archived)
solo-consultazione
Archived
2026-11-04T20:35:50.184Z
SHA-256 of the archived text
fa339f50320793cbe3e1e92a7c9b311e79460d97127d34e4bfe7051a14e4d0c6
Stable URL of this page
https://metraipolis.com/documento/dc_d73b8d0d3702

How to cite

Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy — Europe PMC PMID:41907622 — Europe PMC (en), https://europepmc.org/article/MED/41907622 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d73b8d0d3702 (Metraipolis archive dc_d73b8d0d3702, sha256 fa339f50320793cbe3e1e92a7c9b311e79460d97127d34e4bfe7051a14e4d0c6)
BibTeX
@misc{dcd73b8d0d3702,
  title = {Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy — Europe PMC PMID:41907622},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41907622},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d73b8d0d3702; sha256 fa339f50320793cbe3e1e92a7c9b311e79460d97127d34e4bfe7051a14e4d0c6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41907622. Agents can read the archived copy with the MCP tool read_document.